Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$9.83
-0.12-1.21%
At close: -
$11.24
1.4114.34%
After Hours: May 20, 9:07 AM EDT
Comments
Loading...
Nuvectis Pharma Analyst Ratings and Price Targets | NASDAQ:NVCT | Benzinga
Nuvectis Pharma Inc has a consensus price target of $18 based on the ratings of 4 analysts. The high is $21 issued by Ladenburg Thalmann on July 13, 2022. The low is $15 issued by HC Wainwright & Co. on April 30, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Maxim Group, and Laidlaw & Co. on April 30, 2025, April 2, 2025, and March 17, 2025, respectively. With an average price target of $17 between HC Wainwright & Co., Maxim Group, and Laidlaw & Co., there's an implied 51.25% upside for Nuvectis Pharma Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Maxim Group
Laidlaw & Co.
Ladenburg Thalmann
1calculated from analyst ratings
Analyst Ratings for Nuvectis Pharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/30/2025 | Buy Now | 33.45% | HC Wainwright & Co. | Joseph Pantginis45% | $11 → $15 | Reiterates | Buy → Buy | Get Alert |
| 04/02/2025 | Buy Now | 51.25% | Maxim Group | Naz Rahman28% | → $17 | Initiates | → Buy | Get Alert |
| 03/17/2025 | Buy Now | 69.04% | Laidlaw & Co. | Yale Jen25% | → $19 | Initiates | → Buy | Get Alert |
| 02/25/2025 | Buy Now | -2.14% | HC Wainwright & Co. | Joseph Pantginis45% | $21 → $11 | Maintains | Buy | Get Alert |
| 08/06/2024 | Buy Now | 86.83% | HC Wainwright & Co. | Joseph Pantginis45% | $21 → $21 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | 86.83% | HC Wainwright & Co. | Joseph Pantginis45% | $21 → $21 | Reiterates | Buy → Buy | Get Alert |
| 09/15/2023 | Buy Now | 86.83% | HC Wainwright & Co. | Joseph Pantginis45% | → $21 | Reiterates | Buy → Buy | Get Alert |
| 03/07/2023 | Buy Now | 86.83% | HC Wainwright & Co. | Joseph Pantginis45% | → $21 | Reiterates | → Buy | Get Alert |
| 02/10/2023 | Buy Now | 86.83% | HC Wainwright & Co. | Joseph Pantginis45% | → $21 | Reiterates | → Buy | Get Alert |
| 07/13/2022 | Buy Now | 86.83% | Ladenburg Thalmann | Aydin Huseynov33% | → $21 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Nuvectis Pharma (NVCT) stock?
The latest price target for Nuvectis Pharma (NASDAQ:NVCT) was reported by HC Wainwright & Co. on April 30, 2025. The analyst firm set a price target for $15.00 expecting NVCT to rise to within 12 months (a possible 33.45% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Nuvectis Pharma (NVCT)?
The latest analyst rating for Nuvectis Pharma (NASDAQ:NVCT) was provided by HC Wainwright & Co., and Nuvectis Pharma reiterated their buy rating.
When was the last upgrade for Nuvectis Pharma (NVCT)?
There is no last upgrade for Nuvectis Pharma
When was the last downgrade for Nuvectis Pharma (NVCT)?
There is no last downgrade for Nuvectis Pharma.
When is the next analyst rating going to be posted or updated for Nuvectis Pharma (NVCT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Nuvectis Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Nuvectis Pharma was filed on April 30, 2025 so you should expect the next rating to be made available sometime around April 30, 2026.
Is the Analyst Rating Nuvectis Pharma (NVCT) correct?
While ratings are subjective and will change, the latest Nuvectis Pharma (NVCT) rating was a reiterated with a price target of $11.00 to $15.00. The current price Nuvectis Pharma (NVCT) is trading at is $11.24, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
